NCT05812404

Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects

A Randomized, Open-label, Three-period, Three-sequence, Multiple Dosing Crossover, Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 After Co-administration of DWP14012 and DWC202201 in Healthy Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

A randomized, open-label, three-period, three-sequence, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacokinetics of DWC202201 after co-administration of DWP14012 and DWC202201 in healthy subjects

Conditions

• Drug Drug Interaction

Interventions

Type	Name	Description
DRUG	DWP14012	Potassium-competitive acid blocker
DRUG	DWC202201	Atorvastatin Calcium Trihydrate

Timeline

• Start date: 2022-10-26
• Primary completion: 2023-03-28
• Completion: 2023-06-16
• First posted: 2023-04-13
• Last updated: 2023-04-13

Locations

1 site across 1 country: South Korea